Chen, X., Huang, M., Fang, J., Huang, J., Lin, T. (2025). Intravesical disitamab vedotin (RC48) for patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: A dose-escalation phase I trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4605